Hansen invests in temperature monitoring tech
This article was originally published in Clinica
Hansen Medical has gained exclusive rights to temperature measurement technology, developed by Advanced Cardiac Therapeutics (ACT), for certain robotic applications. In exchange, Hansen made an undisclosed equity investment in the Laguna Beach, California-based firm. According to Hansen (Mountain View, California), existing manual technology used to control catheters in electrophysiology procedures provides only limited precision and stability, and cannot accurately sense tissue temperature and its potential effect on lesion quality. ACT’s microwave radiometry system, when integrated into the catheters used with Hansen’s Sensei robotic catheter system, could provide electrophysiologists with real-time feedback about effective energy delivery in catheters. Financial terms of the deal were not disclosed.
You may also be interested in...
Alere’s professional diagnostics business helped the firm record overall revenue growth in the fourth quarter of 2010, offsetting a fall in influenza-based sales in North America.
Integra LifeSciences has gained exclusive worldwide rights from Stout Medical to develop and commercialise an expandable interbody fusion device.
Gen-Probe recently launched its Panther automated molecular diagnostics system in Europe with the aim of bringing another dimension to its product portfolio. Joseph Harvey met the firm’s CEO, Carl Hull, at the launch of the product in Frankfurt to find how high the firm has set its sights in the molecular diagnostics sector and how it is going to achieve its goals